Cross-cultural evaluation of the modified Parkinson psychosis rating scale across disease stages

Movement Disorders

Volumn 25, Issue 10, 2010, Pages 1391-1398

  Virués Ortega, Javier ^a,e   Rodríguez Blázquez, Carmen ^a   Micheli, Federico ^b   Carod Artal, Francisco Javier ^c   Serrano Dueñas, Marcos ^d   Martínez Martín, Pablo ^a,e  

^a Consortium for Biomed Res in Neurodeg Dis ^*  (Spain)

^b HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^c SARAH NETWORK OF REHABILITATION HOSPITALS   (Brazil)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR   (Ecuador)

^e CARLOS III INSTITUTE OF HEALTH   (Spain)

Author keywords

CISI PD; Parkinson's disease; PPRS; Psychosis

Indexed keywords

ADULT; AGED; ARGENTINA; ARTICLE; BRAZIL; CONTENT VALIDITY; CONTROLLED STUDY; CORRELATION COEFFICIENT; CRONBACH ALPHA COEFFICIENT; CULTURAL FACTOR; DIAGNOSTIC ACCURACY; DISEASE DURATION; DISEASE SEVERITY; ECUADOR; EVALUATION; FACTORIAL ANALYSIS; FEMALE; HALLUCINATION; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MODIFIED PARKINSON PSYCHOSIS RATING SCALE; PARAGUAY; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; VALIDITY;

AGED; CROSS-CULTURAL COMPARISON; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PSYCHOMETRICS; PSYCHOTIC DISORDERS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 77955023785     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23081     Document Type: Article

References (28)

1. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999;56:595-601. (Pubitemid 29218155)
2. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-745. (Pubitemid 30162723)
3. Pappert EJ, Goetz CG, Niederman FG, Raman R, Leurgans S. Hallucinations, sleep fragmentation and altered dream phenomena in Parkinson's disease. Mov Disord 1999;14:117-121. (Pubitemid 29224685)
4. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-695. (Pubitemid 38526677)
5. Fernandez HH, Aarsland D, Fenelon G, et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov Disord 2008;23:484-500.
6. Friedberg G, Zoldan J, Weizman A, Melamed E. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 1998;21:280-284. (Pubitemid 28491427)
7. Mancini F, Tassorelli C, Martignoni E, et al. Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease. Clin Neuropharmacol 2004;27:33-37. (Pubitemid 38280386)
8. Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002;23:41-43. (Pubitemid 34591417)
9. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002. (Pubitemid 44044781)
10. Visser M, Verbaan D, van Rooden SM, et al. Assessment of psychiatric complications in Parkinson's disease: the SCOPA-PC. Mov Disord 2007;22:2221-2228.
11. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007;22:1061-1068. (Pubitemid 47067214)
12. Hughes AJ, Daniel SE, Kliford L, Leeds AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
14. Martínez-Martín P, Rodríguez-Blázquez C, Forjaz MJ, de Pedro J. The clinical impression of severity index for Parkinson's disease: international validation study. Mov Disord 2009;24:211-217.
15. Martínez-Martín P, Frades-Payo B, Rodríguez- Blázquez C, Forjaz MJ, de Pedro-Cuesta J. [Psychometric attributes of Scales for Outcomes in Parkinson's Disease-Cognition (SCOPA-Cog), Castilian language]. Rev Neurol 2008;47:337-343.
16. Virues-Ortega J, Carod-Artal FJ, Serrano-Dueñas M, et al. Cross-cultural validation of the scales for outcomes in Parkinson's disease-psychosocial questionnaire (SCOPA-PS) in four Latin American countries. Value Health 2009;12:385-391.
17. Lorenzo-Seva U, Ferrando PJ. FACTOR: a computer program to fit the exploratory factor analysis model. Behav Res Methods Instrum Comput 2006;38:88-91.
18. Lynn MR. Determination and quantification of content validity. Nurs Res 1986;35:382-385.
19. Remple VP, Hilton BA, Ratner PA, Burdge DR. Psychometric assessment of the multidimensional quality of life questionnaire for persons with HIV/AIDS (MQOL-HIV) in a sample of HIV-infected women. Qual Life Res 2004;13:947-957.
20. Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004;63:293-300.
21. Chou KL, Borek LL, Friedman JH. The management of psychosis in movement disorder patients. Expert Opin Pharmacother 2007;8:935-943.
22. Papapetropoulos S. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 2006;29:59.
23. Juniper EF, Guyatt GH, Jaeschke R. How to develop and validate a new health-related quality of life instrument. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials, second ed. Philadelphia: Lippincott-Raven Publishers; 1996. p 49-56.
24. Fabrigar LR, Wegener DT, MacCallum RC, Strahan EJ. Evaluating the use of exploratory factor analysis in psychological research. Psychol Methods 1999;4:272-299.
25. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, García- Sánchez C, Gironell A. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord 2008;23:1889-1896.
26. Black KJ, Friedman JH. Repetitive and impulsive behaviors in treated Parkinson disease. Neurology 2006;67:2013-2019.
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fourth ed. (Text Revision). Arlington, VA: American Psychiatric Publishing, Inc.; 2000.
28. Wyrwich KW, Bullinger M, Aaronson N, et al. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 2005;14:285-295.